Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
ANTONY J. SABIN
Observed names:
Antony Sabin,
Sabin, Antony James
Institution:
GlaxoSmithKline (United Kingdom)
Observed institutions:
AstraZeneca (United Kingdom),
University of Liverpool,
GlaxoSmithKline (United Kingdom),
Kenya Medical Research Institute,
Amgen (United Kingdom),
AstraZeneca (United States),
Kala-Azar Medical Research Centre,
Banaras Hindu University
show all 8
OpenAlex ID:
A5114037924
A Phase Ii Dose-increasing Study of Sitamaquine for the Treatment of Visceral Leishmaniasis in Kenya
2005
·
MONIQUE K. WASUNNA
, JUMA R. RASHID
, et al.
·
American Journal of Tropical Medicine and Hygiene
·
171
A Phase Ii Dose-ranging Study of Sitamaquine for the Treatment of Visceral Leishmaniasis in India
2005
·
TARA K. JHA
, SHYAM SUNDAR
, et al.
·
American Journal of Tropical Medicine and Hygiene
·
136
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial
2013
·
Charles S. Fuchs
, Marwan Fakih
, et al.
·
Cancer
·
71
PDF
Effects of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine
2001
·
Eliane Fuseau
, Olivier Petricoul
, et al.
·
Clinical Therapeutics
·
45
Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis
2021
·
Khader Shameer
, Youyi Zhang
, et al.
·
Frontiers in Oncology
·
35
PDF
An evaluation of Bayesian designs for dose-escalation studies in healthy volunteers
2005
·
John Whitehead
, Yinghui Zhou
, et al.
·
Statistics in Medicine
·
28
A note on the determination of non-inferiority margins with application in oncology clinical trials
2019
·
Binbing Yu
, Harry Yang
, et al.
·
Contemporary Clinical Trials Communications
·
3
PDF
A Bayesian model averaging method for dose ranging studies in oncology
2026
·
Adetayo Kasim
, Nathan W Bean
, et al.
·
Biometrics
Addressing the Impact of the COVID-19 Pandemic on Survival Outcomes in Randomized Phase III Oncology Trials
2022
·
Jiabu Ye
, Binbing Yu
, et al.
·
Journal of Data Science
PDF
663 Correlation between early endpoints and overall survival in non-small-cell lung cancer: a trial-level meta-analysis
2020
·
Shameer Khader
, Youyi Zhang
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Exaggeration of median progression-free survival (PFS) by blinded, independent, central review (BICR).
2018
·
Andrew Stone
, Val Gebski
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
12
Citation count:
489
H-index:
6
I10-index:
6
Year
Topic
Type